SEATTLE — With increasing survival rates after allogeneic hematopoietic stem cell transplantation (HSCT) in children, dermatologists may be seeing more skin conditions associated with HSCT, including ...

The European Medicines Agency (EMA) has recommended the refusal of marketing authorization for Rezurock (belumosudil) for treating patients 12 years or older with chronic graft-vs-host disease (cGvHD) ...

Hematopoietic cell transplantation (HCT) is a lifesaving treatment for people diagnosed with fatal blood cancers or other blood disorders. The procedure involves replacing the recipient’s blood ...

Paris, October 17, 2025. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion on the marketing authorisation application for Rezurock ...

Graft-versus-host disease (GVHD) following liver transplantation remains a rare but devastating complication, characterised by donor immunocompetent cells initiating an immune attack against host ...

The MarketWatch News Department was not involved in the creation of this content. Results from the Precision-T study showed Orca-T significantly improved survival free from chronic GvHD in patients ...

Certain foods can be unsafe or cause GI pain when you’re managing graft-versus-host disease (GVHD). To prevent uncomfortable symptoms or healing issues, dietitians recommend avoiding these foods.

Transitioning to a 0.6 mg/kg monthly dose of Niktimvo showed a 94.7% overall response rate in cGVHD patients. Increased severe side effects were observed with the monthly dose, likely due to longer ...

Is Unmutated IgG1 a Wrong Choice for Therapeutic Antibodies Targeting Immune Checkpoints? Lessons From the Clinical Failures of the First Anti–TIGIT Antibodies While overall survival (OS) ostensibly ...

If you’re living with chronic graft-versus-host disease (GVHD) — or supporting someone who is — you know this condition rarely affects just one part of the body. When symptoms involve the skin, joints ...